Aurobindo Pharma (AUROPHARMA) — Announcement

📢 Key Event
Aurobindo Pharma incorporates Avogent Lifesciences as wholly owned subsidiary

💡 Investor Takeaway
The subsidiary creation sets up a dedicated platform for future pharma operations but does not affect current financials or shareholder value immediately.

Aurobindo Pharma announced the incorporation of Avogent Lifesciences Private Limited, a wholly owned subsidiary, to handle manufacturing and marketing operations in India and abroad. The new entity was incorporated on August 31, 2026 with an initial paid-up capital of ₹5 crores through 50 lakh equity shares of ₹10 each. This move establishes a dedicated platform for pharma operations but carries no immediate financial impact or regulatory approvals. The filing confirms the subsidiary is a related party transaction with no promoter interest.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Ltd (AUROPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹97,238.86 Cr P/E: 26.4 ROE: 9.8% ROCE: 12.8% Div Yield: 0.24%

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"What is the valuation of Avogent Lifesciences?" "How does Avogent compare to existing pharma subsidiaries?" "What are the projected timelines for manufacturing operations?"

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 1 September 2026

FORTIS Fortis Healthcare Ltd Announcement JNPR Juniper Green Energy Ltd Announcement SUNPHARMA Sun Pharmaceutical Industries Ltd Announcement SUDARSCHEM Sudarshan Chemical Industries Ltd Announcement CGCL Capri Global Capital Ltd Announcement SUDARSCHEM Sudarshan Chemical Industries Ltd Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd